Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo A tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

NCT06279234
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions
Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

NCT01159626
View directory record Official record
Conditions
Healthy
Interventions
PF-03463275, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

NCT01926444
View directory record Official record
Conditions
Pain, Cancer, Colonic Diseases
Interventions
GIC-1001
Drug
Lead sponsor
gicare Pharma Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Anaheim, California • Chula Vista, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol

NCT00682916
View directory record Official record
Conditions
Obesity
Interventions
Y288
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 30, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD3293, Placebo, Moxifloxacin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 30, 2026, 10:07 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

NCT04239014
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib, Ceralasertib, Placebo to match olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

NCT01876784
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Vandetanib (SAR390530), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Torrance, California • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 30, 2026, 10:07 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

NCT04601038
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment
Interventions
CORT108297, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

NCT00548587
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Beloit, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

NCT06619847
View directory record Official record
Conditions
Acute Pain
Interventions
VX-993, HB/APAP, Placebo (matched to VX-993), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

NCT03221426
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

NCT00842816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ST101, Placebo
Drug
Lead sponsor
Sonexa Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658
View directory record Official record
Conditions
Resistant Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

NCT04472598
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Placebo for Navitoclax, Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
35
States / cities
Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

NCT02256540
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Climara, Placebo patch, Resveratrol, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00361335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab, Methotrexate, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
20
States / cities
Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions
Alogliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
292
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Sep 30, 2026, 10:07 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Inhaled Isopropyl Alcohol for Treatment of Nausea

NCT05418244
View directory record Official record
Conditions
Vomiting, Nausea, Children, Only
Interventions
Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo
Other · Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Intensive Rehabilitation

NCT03906721
View directory record Official record
Conditions
Spinal Cord Injuries, Polytrauma, Burn Injury, Pain Management
Interventions
Placebo, Oxycodone, Essential Oil
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 30, 2026, 10:07 AM EDT